KR102423942B1 - 항-tnfrsf25 항체 - Google Patents

항-tnfrsf25 항체 Download PDF

Info

Publication number
KR102423942B1
KR102423942B1 KR1020187035804A KR20187035804A KR102423942B1 KR 102423942 B1 KR102423942 B1 KR 102423942B1 KR 1020187035804 A KR1020187035804 A KR 1020187035804A KR 20187035804 A KR20187035804 A KR 20187035804A KR 102423942 B1 KR102423942 B1 KR 102423942B1
Authority
KR
South Korea
Prior art keywords
leu
antibody
ala
gly
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187035804A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015716A (ko
Inventor
테일러 에이치. 슈라이버
제프 티. 허친스
Original Assignee
펠리칸 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펠리칸 테라퓨틱스, 인코포레이티드 filed Critical 펠리칸 테라퓨틱스, 인코포레이티드
Publication of KR20190015716A publication Critical patent/KR20190015716A/ko
Application granted granted Critical
Publication of KR102423942B1 publication Critical patent/KR102423942B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187035804A 2016-06-09 2017-06-09 항-tnfrsf25 항체 Expired - Fee Related KR102423942B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
US62/348,009 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (2)

Publication Number Publication Date
KR20190015716A KR20190015716A (ko) 2019-02-14
KR102423942B1 true KR102423942B1 (ko) 2022-07-22

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035804A Expired - Fee Related KR102423942B1 (ko) 2016-06-09 2017-06-09 항-tnfrsf25 항체

Country Status (15)

Country Link
US (3) US10005843B2 (enExample)
EP (1) EP3468998B1 (enExample)
JP (1) JP6961625B2 (enExample)
KR (1) KR102423942B1 (enExample)
CN (1) CN109219620B (enExample)
AU (1) AU2017278192A1 (enExample)
BR (1) BR112018075222A2 (enExample)
CA (1) CA3026652A1 (enExample)
DK (1) DK3468998T3 (enExample)
IL (1) IL263406B2 (enExample)
MX (1) MX389320B (enExample)
RU (1) RU2746314C2 (enExample)
SG (1) SG11201810853UA (enExample)
WO (1) WO2017214547A1 (enExample)
ZA (1) ZA201808317B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3148564A1 (en) * 2019-08-30 2021-03-04 Matthew M. Seavey Methods of treating cancer using tnfrsf25 antibodies
WO2021062371A1 (en) * 2019-09-26 2021-04-01 Pelican Therapeutics, Inc. Tnfrsf25-mediated treatments of immune diseases and disorders
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
JP7849919B2 (ja) * 2022-06-17 2026-04-22 セレクシン インコーポレイテッド ヒトｄｒ３に特異的に結合する抗体及びその用途
CN116514983B (zh) * 2023-06-02 2025-05-23 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体及其应用
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
AU2025213136A1 (en) * 2024-01-24 2026-07-16 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
DK1667730T3 (da) 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
DK1919954T3 (en) * 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
FR2907341B1 (fr) 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
ES2586837T3 (es) * 2009-08-03 2016-10-19 University Of Miami Método para la expansión in vivo de linfocitos T reguladores
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
EP2943253B1 (en) 2013-01-09 2021-10-20 University Of Miami Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
CN103592439B (zh) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 人尿路上皮癌特异性抗体及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Also Published As

Publication number Publication date
MX389320B (es) 2025-03-20
US20210017287A1 (en) 2021-01-21
IL263406A (en) 2018-12-31
DK3468998T3 (en) 2022-03-07
AU2017278192A1 (en) 2018-12-13
US10005843B2 (en) 2018-06-26
RU2018143977A3 (enExample) 2020-10-05
EP3468998B1 (en) 2021-12-01
CA3026652A1 (en) 2017-12-14
US20180312599A1 (en) 2018-11-01
RU2018143977A (ru) 2020-07-09
BR112018075222A2 (pt) 2019-03-19
US20170355773A1 (en) 2017-12-14
ZA201808317B (en) 2019-08-28
JP6961625B2 (ja) 2021-11-10
IL263406B2 (en) 2023-09-01
IL263406B1 (en) 2023-05-01
CN109219620B (zh) 2023-01-31
EP3468998A1 (en) 2019-04-17
JP2019526528A (ja) 2019-09-19
KR20190015716A (ko) 2019-02-14
SG11201810853UA (en) 2019-01-30
MX2018014716A (es) 2019-03-11
CN109219620A (zh) 2019-01-15
US10683359B2 (en) 2020-06-16
RU2746314C2 (ru) 2021-04-12
WO2017214547A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
US10683359B2 (en) Anti-TNFRSF25 antibodies
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
KR102950761B1 (ko) 이중특이성 t 세포 맞물림 항체 작제물
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
US10683358B2 (en) Human TNFRSF25 antibody
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
JP2021522801A (ja) ヒトネクチン４に特異的な抗体
CN113412117A (zh) 嵌合抗原和t细胞受体及使用的方法
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
JP2018503399A (ja) 多特異性免疫調節抗原結合構築物
JP2018524997A (ja) Ｅｇｆｒｖｉｉｉ及びｃｄ３に結合する二重特異性抗体構築物
CN109485729A (zh) Bcma和cd3的结合分子
US12071466B2 (en) Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
KR20220012856A (ko) 항 ｐｄ―ｌ１ 항체 및 그의 용도
JP2024514246A (ja) Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用
CN114790241A (zh) 抗tigit抗体及其应用
KR20230159823A (ko) Cd112r에 대한 항체 및 이의 용도
CN116554325A (zh) 抗b7h3抗体及其应用
CN113368232B (zh) 多特异性抗原结合蛋白及其应用
HK40007009B (en) Anti-tnfrsf25 antibodies
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250720

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250720

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250720